Skip to main content
Fig. 5 | BMC Cancer

Fig. 5

From: Raltitrexed enhanced antitumor effect of anlotinib in human esophageal squamous carcinoma cells on proliferation, invasiveness, and apoptosis

Fig. 5

Combinated effects of raltitrexed and anlotinib on cell apoptosis in ESCC cells. A and C KYSE-30 (A) and TE-1 (C) cells were exposed to control, 20 μM anlotinib, 2.5 μM raltitrexed or 20 μM anlotinib + 2.5 μM raltitrexed for 48 h before Annexin V-FITC and 7AAD-PerCP staining and apoptosis percentage was detected by flow cytometry. B and D Quantitative analysis of the apoptotic rate in KYSE-30 (B) and TE-1 (D) cells. Q1 (necrosis), Q2 (late apoptosis), Q3 (early apoptosis) and Q4 (viable). Data indicate means + SD of three biological replicates. Student’s t test; ***P < 0.01 (versus control); ##P < 0.01 (versus 20 μM anlotinib or 2.5 μM raltitrexed)

Back to article page